Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults

BACKGROUND: Malaria elimination requires interruption of the highly efficient transmission of Plasmodium parasites by mosquitoes. TB31F is a humanised monoclonal antibody that binds the gamete surface protein Pfs48/45 and inhibits fertilisation, thereby preventing further parasite development in the...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Boor, Saskia C, Smit, Merel J, van Beek, Stijn W, Ramjith, Jordache, Teelen, Karina, van de Vegte-Bolmer, Marga, van Gemert, Geert-Jan, Pickkers, Peter, Wu, Yimin, Locke, Emily, Lee, Shwu-Maan, Aponte, John, King, C Richter, Birkett, Ashley J, Miura, Kazutoyo, Ayorinde, Morolayo A, Sauerwein, Robert W, ter Heine, Rob, Ockenhouse, Christian F, Bousema, Teun, Jore, Matthijs M, McCall, Matthew B B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605874/
https://www.ncbi.nlm.nih.gov/pubmed/35963275
http://dx.doi.org/10.1016/S1473-3099(22)00428-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605874/
https://www.ncbi.nlm.nih.gov/pubmed/35963275
http://dx.doi.org/10.1016/S1473-3099(22)00428-5

Ejemplares similares